Dr Reddy’s plans generic Ozempic launch in Canada
Key takeaways
- Last month, the company received approval for its generic semaglutide treatment for diabetes from Canada’s health regulator.
- Dr Reddy’s said it expects the contribution of its semaglutide products to be “meaningful”.
- India’s drug regulator has also approved the company’s generic semaglutide tablets, which it aims to launch in the next few days, said M V Ramana, CEO of global generics.
Why this matters: local context for readers following news across Pakistan and the region.
Add ARY News on Google AAResize India’s Dr Reddy’s, which reported an 86% slump in profit on Tuesday, said it aims to launch the generic version of blockbuster diabetes drug Ozempic in Canada in the next few days, as it bets on semaglutide to be a key growth driver.
Last month, the company received approval for its generic semaglutide treatment for diabetes from Canada’s health regulator. Semaglutide is the active component in Danish drugmaker Novo Nordisk’s weight-loss and diabetes drugs Wegovy and Ozempic.
Dr Reddy’s said it expects the contribution of its semaglutide products to be “meaningful”. The patent for semaglutide in India expired in March.